

Shilpa Medicare Limited



Manufacturers and Exporters of Bulk Drugs

10/80, Rajendra Gunj, RAICHUR - 584 102. (INDIA)
Phone : +91-8532-235006,235704 Fax : +91-8532-235876
E-mail : info@vbshilpa.com, Website : www.vbshilpa.com

UNAUDITED FINANCIAL RESULTS FOR THREE MONTHS ENDED 30-06-2011

(Rs.in Lakhs)

Particulars	1st Quarter (Unaudited)				Previous Year (Audited)	
	Standalone		Consolidated		Standalone	Consolidated
	30.06.2011	30.06.2010	30.06.2011	30.06.2010	31.03.2011	31.03.2011
1. (a) Net Sales/Income from Operations	6082.70	6461.43	6832.28	7218.03	25754.35	29028.57
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	6082.70	6461.43	6832.28	7218.03	25754.35	29028.57
2. Expenditure						
a. Increase/decrease in stock in trade and WIP	(1232.01)	797.79	(1285.21)	768.72	883.98	933.79
b. Consumption of raw materials	4835.45	2669.22	4961.09	2917.70	14242.30	15111.33
c. Purchase of traded goods	72.51	27.25	88.40	27.25	299.99	299.99
d. Employees cost	468.96	388.20	870.42	757.24	1758.52	3312.38
e. Exchange - Gain / Loss	(48.31)	145.03	(51.65)	155.95	(378.44)	(379.96)
f. Depreciation	271.37	247.97	340.90	312.81	1042.11	1297.79
g. Other expenditure	403.33	344.15	585.53	507.52	1668.75	2349.80
h. Total	4771.30	4619.61	5509.48	5447.19	19517.21	22925.12
3. Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	1311.40	1841.82	1322.80	1770.84	6237.14	6103.45
4. Other Income	278.88	4.21	279.85	9.78	423.58	407.58
5. Profit before Interest and Exceptional Items (3+4)	1590.28	1846.03	1602.65	1780.62	6660.72	6511.03
6. Interest	27.82	74.58	34.48	77.56	184.75	206.01
7. Profit after Interest but before Exceptional Items (5-6)	1562.46	1771.45	1568.17	1703.06	6475.97	6305.02
8. Exceptional items	0.00	107.17	0.00	107.17	107.67	107.67
9. Profit from Ordinary Activities before tax (7+8)	1562.46	1878.62	1568.17	1810.23	6583.64	6412.69
10. Tax expense	491.12	554.50	491.40	554.50	1491.11	1460.00
11 Profit from Ordinary Activities after tax (9-10)	1071.34	1324.12	1076.77	1255.73	5092.53	4952.69
12. Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
13. Net Profit for the period (11-12)	1071.34	1324.12	1076.77	1255.73	5092.53	4952.69
14. Paid-up equity share capital (Face value of Rs 2/-)	480.48	440.48	480.48	440.48	480.48	480.48
15. Reserves excluding Revaluation Reserves as per previous year B/S.	-	-	-	-	22603.09	21240.49
16. Earnings Per Share (EPS)-Face Value of Rs 2/-						
a) Basic EPS before Extraordinary items	4.46	6.01	4.48	5.70	22.08	21.48
b) Basic diluted EPS after Extraordinary items	4.37	6.01	4.39	5.70	21.84	21.24
17. Public Shareholding	10819724	8819724	10819724	8819724	10819724	10819724
- Percentage of shareholding	45.04	40.05	45.04	40.05	45.04	40.05
18. Promoters & Promoters group Shareholding						
a) Pledged / Encumbered	-	-	-	-	-	-
b) Non encumbered	13204441	13204441	13204441	13204441	13204441	13204441
% of shareholding of promoters & promoter group	100	100	100	100	100	100
% of total Share Capital of the Company	54.96	59.95	54.96	59.95	54.96	54.96

Notes:

- The above results is reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company.
- Figures for the previous period/years have been regrouped/reclassified, wherever necessary, to conform the figures of the current year.
- Shareholders complaints outstanding at the beginning of the quarter- Nil, received- 08 and resolved during the quarter- 08 and pending Nil.
- As per AS-17 reportable segment is only one i.e Bulk Drug & API, therefore, segment reporting is not applicable.
- The Statutory Auditors have carried out the limited review of the above financial results .

By the order of the Board of Directors:
M/S. SHILPA MEDICARE LIMITED



Vishnukant Bhutada
Managing Director